GSK Seeks Re-Entry To Parkinson's Market In Deal With Impax
With no Parkinson's candidates in its pipeline, the pharma pays $11.5 million upfront for ex-U.S. rights to Phase III compound.
With no Parkinson's candidates in its pipeline, the pharma pays $11.5 million upfront for ex-U.S. rights to Phase III compound.